4//SEC Filing
LEVIN JEREMY M 4
Accession 0001256153-25-000004
CIK 0001636651other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:15 PM ET
Size
15.8 KB
Accession
0001256153-25-000004
Insider Transaction Report
Form 4
LEVIN JEREMY M
DirectorCEO
Transactions
- Conversion
Common Stock
2025-12-15+71,000→ 3,687,715 total - Purchase
Series B Convertible Preferred Stock
2025-12-11+71→ 71 total→ Common Stock (71,000 underlying) - Purchase
Series A Warrant (right to buy)
2025-12-11+47,333→ 47,333 totalExercise: $1.40→ Common Stock (47,333 underlying) - Purchase
Series B Warrant (right to buy)
2025-12-11+35,500→ 35,500 totalExercise: $1.40Exp: 2030-10-06→ Common Stock (35,500 underlying) - Conversion
Series B Convertible Preferred Stock
2025-12-15−71→ 0 total→ Common Stock (71,000 underlying)
Holdings
- 35,461(indirect: See Footnote)
Common Stock
Footnotes (6)
- [F1]Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025.
- [F2]The reportable securities are owned directly by Divo Holdings, LLC ("Divo"). The Reporting Person's spouse is the manager of Divo. The Reporting Person disclaims beneficial ownership of the shares held by Divo and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose.
- [F3]The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock.
- [F4]Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.
- [F5]The Series A Warrants will terminate upon the earlier of (a) the 30th calendar day following date on which we publicly announce the clearance of the first of any investigational new drug application, clinical trial application or other foreign equivalent with respect to the clinical development of our OV4071 product candidate; provided that such 30-calendar day period shall not commence unless and until a registration statement covering the resale of the shares of Common Stock issuable upon exercise of the Series A Warrants is effective; and (b) October 6, 2030.
- [F6]Each Series B Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.
Documents
Issuer
Ovid Therapeutics Inc.
CIK 0001636651
Entity typeother
Related Parties
1- filerCIK 0001256153
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 4:15 PM ET
- Size
- 15.8 KB